— Published date: 6/2/2026
Value proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Desc…
— Published date: 4/21/2026
Value Proposition: IL-15 superagonist that utilizes a companion diagnostic to treat atopic dermatitis.
Technology Description
Researchers at Washington University in St. Louis have developed a treatment strategy for atopic dermatitis that uses an IL-15 superagonist, al…
— Published Date: 12/19/2024
Value Proposition: This invention utilizes a protein to enhance T cell expansion for CAR-T cell therapy and other adoptive cellular immunotherapy.
Technology Description
Researchers at Washinton University in St. Louis have developed a mutant AP4 protein that is desig…
— Published Date: 12/19/2024
Value Proposition: New method for expanding T cells against individualized tumor-specific mutational antigens.
Technology Description
Researchers at Washington University in St. Louis have developed a device that enables high-throughput production of patient specific …
— Technology Description
Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS).
Most patients with MS present with relapsing remitting MS (RRM…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
